Definition and epidemiology
Hypoglycemia is defined biochemically as a plasma glucose low enough to produce autonomic (adrenergic) or neuroglycopenic symptoms, typically below 70 mg/dL (3.9 mmol/L) in diabetic patients, though the threshold for symptoms varies by individual. Severe hypoglycemia is defined clinically as an episode requiring assistance from another person to recover, regardless of the exact glucose value.
It is overwhelmingly a complication of diabetes mellitus treatment, occurring in a substantial proportion of insulin-treated type 1 diabetics at least once per year and less frequently in type 2 diabetics on insulin or sulfonylureas. Non-diabetic (spontaneous) hypoglycemia is uncommon and prompts a search for an underlying cause such as insulinoma, adrenal insufficiency, or critical illness.
Risk is higher in older adults, those with long-standing diabetes and impaired counterregulation, renal impairment (reduced insulin clearance), and strict glycemic control targets.
- Whipple's triad = symptoms + documented low glucose + relief with glucose administration
- Insulin and sulfonylureas (not metformin or DPP-4 inhibitors alone) are the main diabetes drugs causing hypoglycemia
- Adrenergic symptoms (sweating, tremor, palpitations) usually precede neuroglycopenic symptoms (confusion, seizure)
- Insulinoma: elevated insulin AND elevated C-peptide during a hypoglycemic episode (endogenous source)
- Exogenous insulin use: elevated insulin but LOW C-peptide (suppressed endogenous production)
- 72-hour fast is the gold-standard test for suspected insulinoma or other spontaneous hypoglycemia
- Unconscious hypoglycemic patient: never give oral glucose; use IM/intranasal glucagon or IV dextrose
- Recurrent hypoglycemia causes hypoglycemia unawareness via blunted counterregulatory hormone response
Etiology and risk factors
Diabetic hypoglycemia (most common)
- Insulin overdose or mismatched timing relative to meals
- Sulfonylureas and meglitinides (less so with metformin, DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 agonists alone)
- Missed or delayed meals, increased exercise, alcohol intake
- Renal or hepatic impairment reducing drug clearance
- Hypoglycemia unawareness from recurrent episodes blunting counterregulatory response
Non-diabetic causes
- Insulinoma (endogenous hyperinsulinism)
- Factitious hypoglycemia (surreptitious insulin or sulfonylurea use)
- Alcohol use (impairs gluconeogenesis, especially with poor nutritional intake)
- Adrenal insufficiency, hypopituitarism
- Severe sepsis, liver failure, or renal failure
- Non-islet cell tumors (rare, via IGF-2 production)
- Post-bariatric surgery (late dumping-related reactive hypoglycemia)
- Neonatal causes: maternal diabetes, prematurity, inborn errors of metabolism
Pathophysiology
Normally, falling glucose triggers a sequence of counterregulatory responses: insulin secretion decreases first, followed by increased glucagon, epinephrine, cortisol, and growth hormone, which together stimulate hepatic glycogenolysis and gluconeogenesis.
In insulin-treated diabetes, exogenous insulin cannot be shut off when glucose falls, and glucagon response is often impaired (partly due to loss of intra-islet insulin signaling), making these patients dependent on epinephrine and symptom awareness to prevent severe episodes.
Recurrent hypoglycemia causes hypoglycemia-associated autonomic failure, raising the glycemic threshold for counterregulatory hormone release and blunting adrenergic warning symptoms, so neuroglycopenic symptoms may appear without warning.
The brain depends almost exclusively on glucose for fuel; neuroglycopenia from insufficient glucose delivery produces cognitive and neurologic dysfunction, while catecholamine release produces the adrenergic symptom complex.
Clinical features
Autonomic (adrenergic) symptoms
- Sweating, tremor, palpitations
- Anxiety, hunger
- Pallor
Neuroglycopenic symptoms
- Confusion, difficulty concentrating
- Blurred vision, slurred speech
- Behavioral changes, dizziness
- Seizures, coma if severe or prolonged
Adrenergic symptoms typically precede neuroglycopenic ones and serve as a warning, but this order is lost in hypoglycemia unawareness. Nocturnal hypoglycemia may present only as morning headache, night sweats, or vivid dreams/nightmares.
Diagnosis
Diagnosis rests on Whipple's triad: (1) symptoms consistent with hypoglycemia, (2) a low plasma glucose measured at the time of symptoms, (3) resolution of symptoms after glucose is raised.
In known diabetics on insulin or sulfonylureas with typical symptoms and a low glucose, no further workup is needed beyond treatment and medication review.
For suspected spontaneous (non-diabetic) hypoglycemia, a supervised 72-hour fast with monitoring of glucose, insulin, C-peptide, proinsulin, and beta-hydroxybutyrate is the diagnostic standard:
| Finding | Interpretation |
|---|---|
| High insulin, high C-peptide | Endogenous hyperinsulinism (insulinoma, sulfonylurea use) |
| High insulin, low C-peptide | Exogenous insulin administration |
| Low insulin, low C-peptide | Non-insulin-mediated cause (e.g., adrenal insufficiency, liver failure) |
Sulfonylurea screen distinguishes factitious sulfonylurea use from insulinoma when both insulin and C-peptide are elevated. Imaging (CT, MRI, endoscopic ultrasound) localizes an insulinoma once biochemically confirmed.
Differential diagnosis
- Panic attack or anxiety disorder (adrenergic symptoms without true hypoglycemia)
- Seizure disorder of other etiology
- Transient ischemic attack or stroke (focal neurologic signs)
- Vasovagal syncope
- Alcohol intoxication
- Adrenal insufficiency (overlapping fatigue, hypotension)
- Factitious disorder (surreptitious insulin/sulfonylurea use)
Management
Acute treatment
- Conscious patient able to swallow: 15-20 g of fast-acting oral carbohydrate (glucose tablets or juice), recheck glucose in 15 minutes, repeat if still low, then give a longer-acting carbohydrate/meal (the "15-15 rule")
- Unconscious or unable to swallow safely: intramuscular or intranasal glucagon, or IV dextrose if IV access and personnel are available
- Sulfonylurea-induced hypoglycemia can be prolonged and recurrent, often requiring observation and dextrose infusion for an extended period
Longer-term prevention
- Review and adjust insulin or sulfonylurea regimen, timing, and dosing
- Diabetes education on carbohydrate counting, exercise planning, and glucose monitoring (continuous glucose monitors reduce hypoglycemia risk)
- Relax overly strict glycemic targets in patients with hypoglycemia unawareness or limited life expectancy
- Treat the underlying cause in non-diabetic hypoglycemia (surgical resection for insulinoma, glucocorticoid replacement for adrenal insufficiency, nutritional support for alcohol-related cases)
- Glucagon kits (including newer ready-to-use nasal and auto-injector formulations) should be prescribed to at-risk insulin-treated patients and their contacts educated on use
Complications and prognosis
Most mild-to-moderate episodes resolve fully with prompt treatment. Repeated hypoglycemia, however, worsens hypoglycemia unawareness, creating a vicious cycle of increasingly severe episodes.
Severe or prolonged hypoglycemia can cause seizures, coma, permanent neurologic injury, and is associated with increased cardiovascular events and mortality, particularly in older adults and those with cardiovascular disease.
Severe hypoglycemia is also a leading cause of diabetes-related emergency department visits and a major barrier to achieving tight glycemic control. With appropriate regimen adjustment and education, recurrence risk can be substantially reduced; insulinoma has an excellent prognosis after surgical resection.
"TIRED" for hypoglycemia symptoms: Tremor, Irritability, Racing heart/sweating, Enervation (weakness), Dizziness/confusion — adrenergic signs before neuroglycopenic decline.
Practice questions
1. A 58-year-old man with type 2 diabetes on glyburide and metformin is brought to the emergency department after being found confused and diaphoretic at home. Fingerstick glucose is 38 mg/dL. He is given IV dextrose with improvement, but his glucose drops again 4 hours later despite eating. Which of the following best explains the recurrent hypoglycemia?
2. A 34-year-old woman with no history of diabetes presents with recurrent episodes of confusion and sweating that occur before breakfast and resolve after eating. During a supervised fast, her symptoms recur with a plasma glucose of 42 mg/dL, insulin level markedly elevated, and C-peptide also elevated. Which of the following is the most likely diagnosis?
3. A 22-year-old woman with type 1 diabetes reports that she no longer feels warning symptoms before her glucose drops dangerously low, and she has had three episodes of severe hypoglycemia requiring assistance in the past month. Which of the following is the best next step in management?
Frequently asked questions
What causes hypoglycemia?
The most common cause is diabetes treatment with insulin or sulfonylureas, especially after a missed meal, extra exercise, or alcohol intake. In people without diabetes, causes include insulinoma, adrenal insufficiency, severe liver or kidney disease, sepsis, and alcohol use with poor nutrition. Factitious use of insulin or sulfonylureas is an important cause to consider.
What are the first symptoms of hypoglycemia?
The earliest symptoms are usually adrenergic: sweating, tremor, palpitations, anxiety, and hunger. As glucose falls further, neuroglycopenic symptoms follow, including confusion, blurred vision, slurred speech, and dizziness. Severe untreated hypoglycemia can progress to seizures or loss of consciousness.
How is hypoglycemia diagnosed?
Diagnosis uses Whipple's triad: symptoms consistent with hypoglycemia, a plasma glucose measured as low at that time, and resolution of symptoms once glucose is corrected. In diabetics on insulin or sulfonylureas this is usually straightforward. In non-diabetics, a supervised 72-hour fast with insulin, C-peptide, and proinsulin levels is used to find the cause.
Is hypoglycemia curable?
It depends on the cause. Hypoglycemia from diabetes medication is managed, not cured, through dose adjustment, education, and monitoring, and episodes can recur if risk factors persist. Hypoglycemia from insulinoma is often curable with surgical removal of the tumor, and cases from adrenal insufficiency improve substantially with hormone replacement.
Hypoglycemia vs panic attack — what is the difference?
Both can cause sweating, tremor, palpitations, and anxiety, but hypoglycemia is confirmed by a low plasma glucose at the time of symptoms, while a panic attack occurs with normal glucose levels. Hypoglycemia also tends to produce neuroglycopenic features like confusion or slurred speech, which panic attacks typically do not cause. Checking glucose during an episode distinguishes the two.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E16.2
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.